Summary:
A Phase 1, randomized, parallel group, single-dose clinical pharmacology study to investigate the safety, tolerability, and pharmacokinetics of two different concentrations of sotrovimab administered in male or female healthy participants aged 18 to 65 years.
Qualified Participants Must:
• Be 18-65 years old
•
Have completed the COVID-19 vaccine series (Booster NOT required)
•
Be in general good health
•
Be negative for COVID-19
•
Have a BMI of 18-30 kg/m2
Qualified Participants May Receive:
- Up to $6,535 for time and travel
- No insurance needed and transportation available